[ad_1]
Antiviral medicine bottle remdesivir, em April 8, 2020, in Hamburg, Alemanha (Credit: POOL / AFP / Arquivos)
->
The American laboratory Gilead opened the patent on or antiviral remdesivir to facilitate its access in 127 countries, not yet, or Brazil is listed. Or drug presented moderately positive results not treatment against Covid-19. As informações são do jornal Folha de S.Paulo.
A company idea to facilitate or access and to diminution of the price of medicine we locais contemplated. As companies that assassinate or agree with the Cipla, Ferozsons, Hetero, Jubilant and Mylan laboratories. They will be able to fix or value the generic product to sell our countries in which we are going, to most of the poor countries of Latin America, Asia and Africa.
Second to Folha, the list also included some countries with medium income, regional powers and emerging states, such as Africa do Sul, Egito, Nigéria, Índia, Indonésia, Paquistão, Tailândia and Ucrânia. Rich countries ficaram de fora. In América do Sul, only Guiana and Suriname were included.
Segundo Anvisa (Agência Nacional de Vigilância Sanitária), or use of remdesivir is also not allowed in Brazil. Not the last day 6, I had a first meeting with Gilead to discuss commercialization of the antiviral non-Brazilian market.
“A Gilead feared several clinical trials in walking for or releasing, with initial expectations expected in the coming weeks. Case or benefit of the medication is proven, to Anvisa, I have mechanisms to guarantee or access the medicine to the population, “said the agency in a note.
